Table 3 Different format of Nbs in clinical trials or market
From: A comprehensive comparison between camelid nanobodies and single chain variable fragments
Format | Antibody fragment | Target | Disease | Clinical trials | Phase | Status | Last update / approval date | Sponser |
|---|---|---|---|---|---|---|---|---|
Unconjugated neutralizing agent | ALX-0081 Caplacizumab | von Willebrand Factor | Thrombocytopenic Purpura | NCT02553317 | 3 | FDA approved | Feb 2019 | Ablynx |
ALX-0061 Vobarilizumab | Interleukin 6 receptor (IL6R) | Systemic lupus erythematosus | NCT02437890 | 2 | Completed | Feb 2019 | Ablynx | |
Rheumatoid Arthritis | NCT02287922 | 2 | Completed | Aug 2019 | ||||
ALX-0651 | CXCR4 | Healthy Volunteers | NCT01374503 | 1 | Terminated | Apr 2012 | Ablynx | |
PF-05230905 | CXCR4 | Healthy | NCT01284036 | 1 | Completed | Jan 2013 | Ablynx | |
ALX-0171 | respiratory syncytial virus (RSV) | RSV infection | NCT02979431 | 2 | Completed | Oct 2019 | Ablynx | |
ALX-0761 | IL17A, IL17F and IL17A/F | Psoriasis | NCT03384745 | 2 | Completed | Aug 2021 | Avillion | |
MSB0010841 | IL17A/F | Psoriasis | NCT02156466 | 1 | Completed | Jan 2017 | Merck | |
ATN-103 Ozoralizumab | TNF | Rheumatoid Arthritis | NCT01063803 | 2 | Completed | Apr 2016 | Ablynx | |
KN035 | PD-L1 | Breast cancer Hepatocellular carcinoma | NCT04034823 | 2 | Not yet Recruiting | July 2019 | 3D Medicines (Sichuan) | |
KN044 | CTLA-4 | Advanced Solid Tumors | NCT04126590 | 1 | Recruiting | July 2021 | Changchun Intellicrown Pharmaceutical | |
M6495 | ADAMTS-5 | Osteoarthritis, Knee | NCT03583346 | 1 | Completed | Jan 2020 | Merck | |
LMN-101 | Flagellin filament protein | Campylobacter Infections | NCT04182490 | 2 | Not yet recruiting | Aug 2020 | Lumen Bioscience | |
VHH batch 203027 | Rotavirus | Rotavirus Diarrhoea | NCT01259765 | 2 | Completed | Aug 2011 | International Centre for Diarrhoeal Disease Bangladesh | |
n3088 n3130 Colchicine | SARS Cov2 | COVID-19 | NCT04322682 | 3 | Completed | Jan 2021 | Montreal Heart Institute | |
TAS266 | DR5 | Solid tumors | NCT01529307 | 1 | Terminated | Dec 2020 | Novartis | |
BI 836880 | VEGF/Ang2 | Neoplasm Metastasis | NCT03697304 | 2 | Recruiting | Aug 2021 | Boehringer Ingelheim | |
Conjugated to therapeutic payloads | L-DOS47 | CEACAM6 | Pancreas cancer Lung adenocarcinoma | NCT04203641 NCT03891173 | 2 | Recruiting | Apr 2021 | Helix BioPharma |
Antigen binding domain of Synthetic receptors | TC-210 T Cells | Mesothelin | Mesothelioma Cholangiocarcinoma Ovarian Cancer Non Small Cell Lung Cancer | NCT03907852 | 1&2 | Recruiting | June 2021 | TCR2 Therapeutics |
BCMA CAR T cell | BCMA | Myeloma | NCT03664661 | 1 | Unknown | Sep 2018 | Henan Cancer Hospital | |
CD19/20 bispecific CAR T cell | CD19 and CD20 | B-Cell Lymphoma | NCT03881761 | 1 | Recruiting | Mar 2019 | Henan Cancer Hospital | |
αPD1-MSLN CAR T cell | MSLN | Colorectal cancer Ovarian cancer | NCT04503980 | 1 | Recruiting | Aug 2020 | Shanghai Cell Therapy Group | |
Molecular imaging | 131I-SGMIB Anyi-HER2 VHH1 | HER2 | Breast cancer | NCT02683083 | 1 | Completed | Aug 2019 | Precirix |
68GaNOTA Anti-HER2 VHH1 | HER2 | Breast cancer | NCT03331601 | 2 | Recruiting | Feb 2021 | Universitair Ziekenhuis Brussel | |
99mTc-NM-02 | HER2 | Breast cancer | NCT04040686 | 1 | Recruiting | Dec 2020 | Shanghai General Hospital | |
99mTc-Anti-PD-L1 | PD-L1 | Non-small cell lung cancer | NCT02978196 | 1 | Completed | Aug 2020 | Shanghai General Hospital | |
99mTc MIRC208 | HER2 | Cancer | NCT04591652 | NA | Recruiting | Oct 2020 | Beijing Cancer Hospital | |
68GaNOTA Anti-MMR VHH2 | Macrophage Mannose Receptor (MMR) | Breast cancer Head and Neck Cancer Melanoma Carotid Stenosis Atherosclerosis of Artery | NCT04758650 | 2 | Recruiting | Feb 2021 | Universitair Ziekenhuis Brussel |